Prelude Therapeutics Inc (PRLD) Stock Price, Quote & News

Company Profile

Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT3789, a selective degrader of SMARCA2 protein for the treatment of advanced or metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion; PRT7732, a selective and orally bioavailable SMARCA2 degraders to treat advanced or metastatic solid tumors; and PRT2527, a cyclin...

Industry: Biotechnology

Sector: Healthcare

Phone: 302 467 1280

Website: preludetx.com

Address:

175 Innovation Boulevard, Wilmington, United States

Dizzier47 Nov. 13 at 6:24 PM

$PRLD in a sea of red i see a green ticker and it's this

0 · Reply

SPYmyQQQ Nov. 12 at 9:17 PM

🎯 Target Hit 🏁 📨 From Nov 7, 2025 💊 $PRLD 💵 Entry: $1.2600 ✅ Exit: $1.4500 💰 P/L: +15.08% 👉 FREE TRIAL! spymyqqq/join/

1 · Reply

SPYmyQQQ Nov. 12 at 9:17 PM

🎯 Target Hit 🏁 📨 From Nov 10, 2025 💊 $PRLD 💵 Entry: $1.2200 ✅ Exit: $1.4500 💰 P/L: +18.85% 👉 FREE TRIAL! spymyqqq/join/

0 · Reply

LabPsycho Nov. 12 at 8:55 PM

$PRLD Ugh - just get it over with and announce converting to trading digital dodads like LPTX and claim to still be working on your drug development. Multilayer Ponzi schemes seem the only way left to make money with the market seemingly topped out.

2 · Reply

danial88 Nov. 12 at 8:30 PM

$PRLD 🤫 don’t tag other tickers here !!

1 · Reply

Stmkr Nov. 12 at 3:28 PM

$PRLD $CCCC $NRIX DACs the next big thing in oncology

1 · Reply

BobBijawklah Nov. 12 at 3:04 PM

$PRLD this stock is a pleasant a fragrance as preston

1 · Reply

Wed21 Nov. 12 at 2:44 PM

$PRLD lets go. 2 today on the cards!

0 · Reply

Kevvinn Nov. 12 at 1:42 PM

$PRLD any price prediction today?

1 · Reply

Dizzier47 Nov. 12 at 12:56 PM

$PRLD why do ppl think that a biotech company spending 8 mil less on R&D is good earnings lol

1 · Reply

Prelude Therapeutics Incorporated (PRLD) Q3 2025 Earnings Call Transcript

Nov 12, 2025, 7:01 AM EST - 2 days ago

Prelude Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 11, 2025, 11:24 PM EST - 3 days ago

PRLD Investors Have Opportunity to Join Prelude Therapeutics Incorporated Fraud Investigation With the Schall Law Firm

Nov 4, 2025, 7:05 AM EST - 10 days ago

Prelude Therapeutics Announces Strategic Business Update

Nov 4, 2025, 7:01 AM EST - 10 days ago

Prelude Therapeutics Announces Exclusive Option Agreement with Incyte to Advance Mutant Selective JAK2V617F JH2 Inhibitors

Nov 3, 2025, 9:01 AM EST - 11 days ago

Prelude Therapeutics Announces Publication of Abstracts for Presentation at the American Society of Hematology 67th Annual Meeting

Oct 17, 2025, 7:30 AM EDT - 4 weeks ago

Prelude Therapeutics Announces Appointment of Katina Dorton, J.D., MBA to its Board of Directors

Aug 14, 2025, 7:00 AM EDT - 3 months ago

Prelude Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Jun 2, 2025, 7:30 AM EDT - 5 months ago

Prelude Therapeutics to Participate in Upcoming Healthcare Conferences

May 6, 2025, 4:05 PM EDT - 6 months ago

Prelude Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 1, 2025, 7:30 AM EDT - 7 months ago

Prelude Therapeutics to Participate in Citizens Life Sciences Conference

Apr 25, 2025, 4:05 PM EDT - 7 months ago

Prelude Announces Presentations at 2025 AACR Annual Meeting

Mar 10, 2025, 7:30 AM EDT - 8 months ago

Prelude Therapeutics Reports Full Year 2024 Financial Results and Provides Program Outlook for 2025

Mar 5, 2025, 7:30 AM EST - 9 months ago

Prelude Therapeutics to Participate in Barclays 27th Annual Global Healthcare Conference

$Prelude Therapeutics Presents Preliminary Results of Phase 1 Dose-escalation Study of PRT2527 as Monotherapy and in Combination with Zanubrutinib in Patients with Relapsed/Refractory Lymphoid Malignancies$

Dec 11, 2024, 7:30 AM EST - 1 year ago

Prelude Therapeutics Presents Preliminary Results of Phase 1 Dose-escalation Study of PRT2527 as Monotherapy and in Combination with Zanubrutinib in Patients with Relapsed/Refractory Lymphoid Malignancies

Nov 27, 2024, 7:30 AM EST - 1 year ago

Prelude Therapeutics to Participate in Citizens JMP Securities Hematology and Oncology Summit

Oct 24, 2024, 7:30 AM EDT - 1 year ago

Prelude Therapeutics Presents New Data from SMARCA Degrader Portfolio at the 36th EORTC-NCI-AACR Symposium

Oct 9, 2024, 7:30 AM EDT - 1 year ago

Prelude Therapeutics Announces Publication of Abstracts for Presentation at the 36th EORTC-NCI-AACR Symposium

Sep 13, 2024, 10:00 AM EDT - 1 year ago

Prelude Therapeutics' SMARCA2 Degrader PRT3789 Demonstrated Promising Initial Clinical Activity and Safety Profile in Phase 1 Trial

Sep 9, 2024, 7:30 AM EDT - 1 year ago

Prelude Therapeutics Announces Publication of Abstract for Presentation at the European Society of Medical Oncology (ESMO) Congress 2024

Aug 12, 2024, 7:01 AM EDT - 1 year ago

Prelude Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Jul 9, 2024, 7:30 AM EDT - 1 year ago

Prelude Therapeutics Announces Clinical Collaboration with Merck to Evaluate PRT3789 in Combination with KEYTRUDA® (pembrolizumab) in Patients with SMARCA4-Mutated Cancers

May 9, 2024, 7:01 AM EDT - 1 year ago

Prelude Therapeutics to Participate in Citizens JMP Life Sciences Conference

May 7, 2024, 7:01 AM EDT - 1 year ago

Prelude Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

Apr 9, 2024, 4:35 PM EDT - 1 year ago

Prelude Highlights Continued Strength of Discovery Engine at 2024 AACR Annual Meeting

Mar 5, 2024, 4:45 PM EST - 1 year ago

Prelude Announces Acceptance of Multiple Preclinical Abstracts at the 2024 AACR Annual Meeting

Feb 29, 2024, 4:05 PM EST - 1 year ago

Prelude Therapeutics to Participate in Barclays Global Healthcare Conference

Feb 15, 2024, 4:05 PM EST - 1 year ago

Prelude Therapeutics Reports Full Year 2023 Financial Results and Outlines Key Objectives for 2024

Dec 11, 2023, 9:34 AM EST - 2 years ago

Prelude Therapeutics Announces $25 Million Private Placement

Nov 1, 2023, 4:10 PM EDT - 2 years ago

Prelude Announces Strategic Pipeline Progress and Updates, including its Partnership with AbCellera, and Reports Third Quarter Financial Results

Oct 14, 2023, 12:30 PM EDT - 2 years ago

Prelude Announces Multiple Clinical and Preclinical Poster Presentations at AACR-NCI-EORTC International Conference

Aug 29, 2023, 8:30 AM EDT - 2 years ago

Prelude Therapeutics to Participate in Three Healthcare Investor Conferences in September

Aug 3, 2023, 8:00 AM EDT - 2 years ago

Prelude Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update

May 31, 2023, 8:30 AM EDT - 2 years ago

Prelude Therapeutics To Participate in Jefferies Healthcare Conference

May 17, 2023, 4:08 PM EDT - 2 years ago

Prelude Therapeutics Announces Launch of Proposed Public Offering

May 8, 2023, 8:30 AM EDT - 2 years ago

Prelude Therapeutics Announces First Quarter 2023 Financial Results and Operations Update

Apr 27, 2023, 8:30 AM EDT - 2 years ago

Prelude Therapeutics to Participate in Three Healthcare Investor Conferences in May

Apr 11, 2023, 8:30 AM EDT - 2 years ago

Prelude Therapeutics to Present at American Association for Cancer Research 2023 Conference

Mar 15, 2023, 8:30 AM EDT - 2 years ago

Prelude Therapeutics Reports Full Year 2022 Financial Results and Provides Corporate Update

Mar 15, 2023, 8:00 AM EDT - 2 years ago

Prelude Therapeutics Announces Clinical Trial Collaboration with BeiGene to Evaluate PRT2527 in Combination with Zanubrutinib in Hematologic Cancers

Feb 9, 2023, 9:05 AM EST - 3 years ago

Prelude Therapeutics To Participate in Two Upcoming Healthcare Investor Conferences

Nov 14, 2022, 8:00 AM EST - 3 years ago

Prelude Therapeutics Announces Third Quarter 2022 Financial Results and Provides Business Update

Aug 9, 2022, 8:00 AM EDT - 3 years ago

Prelude Therapeutics Announces Second Quarter 2022 Financial Results and Business Update

May 10, 2022, 8:00 AM EDT - 3 years ago

Prelude Therapeutics Announces First Quarter 2022 Financial Results and Operations Update

Mar 16, 2022, 7:30 AM EDT - 3 years ago

Prelude Therapeutics Reports Full Year 2021 Financial Results

Mar 11, 2022, 8:00 AM EST - 4 years ago

Prelude Therapeutics to Participate at the Barclays 2022 Global Healthcare Conference

Mar 9, 2022, 8:05 AM EST - 4 years ago

Prelude Therapeutics Provides Clinical Update and Announces Presentation of New Preclinical Data at the Upcoming 2022 AACR Annual Meeting

Feb 11, 2022, 7:00 AM EST - 4 years ago

Prelude Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference

Jan 4, 2022, 7:00 AM EST - 4 years ago

Prelude Therapeutics to Present at the H.C. Wainwright BioConnect Virtual Conference

Nov 23, 2021, 7:00 AM EST - 4 years ago

Prelude Therapeutics to Participate at the 4th Annual Evercore ISI HealthCONx Conference

Dizzier47 Nov. 13 at 6:24 PM

$PRLD in a sea of red i see a green ticker and it's this

0 · Reply

SPYmyQQQ Nov. 12 at 9:17 PM

🎯 Target Hit 🏁 📨 From Nov 7, 2025 💊 $PRLD 💵 Entry: $1.2600 ✅ Exit: $1.4500 💰 P/L: +15.08% 👉 FREE TRIAL! spymyqqq/join/

1 · Reply

SPYmyQQQ Nov. 12 at 9:17 PM

🎯 Target Hit 🏁 📨 From Nov 10, 2025 💊 $PRLD 💵 Entry: $1.2200 ✅ Exit: $1.4500 💰 P/L: +18.85% 👉 FREE TRIAL! spymyqqq/join/

0 · Reply

LabPsycho Nov. 12 at 8:55 PM

2 · Reply

danial88 Nov. 12 at 8:30 PM

$PRLD 🤫 don’t tag other tickers here !!

1 · Reply

Stmkr Nov. 12 at 3:28 PM

$PRLD $CCCC $NRIX DACs the next big thing in oncology

1 · Reply

BobBijawklah Nov. 12 at 3:04 PM

$PRLD this stock is a pleasant a fragrance as preston

1 · Reply

Wed21 Nov. 12 at 2:44 PM

$PRLD lets go. 2 today on the cards!

0 · Reply

Kevvinn Nov. 12 at 1:42 PM

$PRLD any price prediction today?

1 · Reply

Dizzier47 Nov. 12 at 12:56 PM

$PRLD why do ppl think that a biotech company spending 8 mil less on R&D is good earnings lol

1 · Reply

EsotericDark Nov. 12 at 12:45 PM

$PRLD For reference: Expected earnings was -0.365 per share. Actual earnings reported was -0.26 per share. That's good news.

0 · Reply

Wed21 Nov. 12 at 12:37 PM

$PRLD great earnings.

0 · Reply

FireIn Nov. 12 at 12:21 PM

$PRLD Prelude quietly printing the most constructive quarter so far: EPS -0.26 (beat) Rev $6.5 M (Incyte payment?) R&D -20% QoQ

2 · Reply

stockexchange01 Nov. 12 at 12:00 AM

$PRLD

0 · Reply

Dizzier47 Nov. 11 at 10:33 PM

$PRLD come on please dump 15% so I can justify buying

1 · Reply

JBurckhardt Nov. 11 at 9:57 PM

$PRLD total equity value = ~$6.05/share

0 · Reply

Buyitsellit2025 Nov. 11 at 9:01 PM

$PRLD I spy lots of green candles …. Is this earnings ?

0 · Reply

elitechrisvp Nov. 11 at 8:31 PM

$PRLD a.m. earnings 😎✅️

0 · Reply

JBurckhardt Nov. 11 at 6:52 PM

$PRLD the deal is done. The fact that this is trading lower than it was before the deal makes no sense. Obvious winner here...

1 · Reply

EsotericDark Nov. 11 at 4:47 PM

$PRLD Holding for tomorrow. With all the Institutional Investment, and the recent deals, I'm cautiously optimistic. Entry was just below $1.50

1 · Reply

Dragan7 Nov. 11 at 12:07 PM

$PRLD A lot of talks. Wait for tomorrow. Many things will be clear. INCY deal is real, pipelines are solid. Place your bets.

1 · Reply

MarketMasterMind Nov. 10 at 6:04 PM

$BQ | $PRLD loading up 🤑Ⓜ️

2 · Reply

Market Cap	85.47M
Revenue (ttm)	7.00M
Net Income (ttm)	-127.17M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-1,816.71%
Debt to Equity Ratio	0.00

Volume	572,400
Avg Vol	1,604,660
Day's Range	N/A - N/A
Shares Out	56.60M
Stochastic %K	34%
Beta	1.37
Analysts	Sell
Price Target	$3.25